Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and after conducting pre-clinical studies in mice at our company, submitted the results of their research to Nature Biotechnology.
This article identifies TRAF2- and NCK-interacting kinase (TNIK) as an anti-fibrotic target using AI and describes the results of pre-clinical and clinical trials in animal models of lung, skin and kidney fibrosis.
It has been observed that the same compound shows its therapeutic effect on fibrosis across multiple organs as described above.
In the past, some companies have evaluated the same compound across multiple organs, such as the liver, lungs, kidneys, intestines and skin, in the development of fibrosis-related therapeutics and have proceeded with the development for diseases that showed particularly promising results.
We believe, the reason that we receive requests like the one mentioned above, is due to our experience and track record of conducting studies with more than 1,000 companies focusing particularly on the pathological evaluation of inflammatory and fibrotic diseases.